Fig. 4: lncRNA-6195 inhibits tumorigenesis of HepG2 cells in vivo. | Cell Death & Disease

Fig. 4: lncRNA-6195 inhibits tumorigenesis of HepG2 cells in vivo.

From: A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1

Fig. 4

a HepG2 cells stably transfected with pcDNA3.1-6195 or pcDNA3.1 vectors were implanted subcutaneously into nude mice (n = 6), respectively. These photos show the tumor xenografts 24 days after inoculation. LncRNA-6195-overexpressed HepG2 cells attenuate tumor growth in vivo. b The volumes of the subcutaneous tumors which were measured every 6 days after implantation. c, d The tumor weight and tumor weight/body weight ratio of two groups. e Subcutaneous tumors tissue sections were subjected to HE stain (magnification: ×200) or Ki-67 IHC analysis (magnification: ×200; ×400). f Assessment of the Ki-67 protein expression in two groups shows that subcutaneous tumors of LncRNA-6195 upregulated group express lower Ki-67 than the control group. (*P < 0.05, ***P < 0.001. Student’s t test. Data are shown as mean ± SD.)

Back to article page